Acute myeloid leukaemia (AML) is a rapidly progressing haematological cancer with a poor prognosis. This infographic summarises the key results from an online survey conducted in 2022 on the perceptions of AML treatments among clinicians in Europe. Haematologists and oncologists from five European countries were asked their opinions on topics such as first-line treatments, the intensity of treatment regimens, and therapies for curative intent for patients with AML.
This Infographic was developed and funded by Jazz Pharmaceuticals and is intended for European Healthcare Professionals only.
